KOMBITROPIL
Active material: Tsinnarizin, Piracetam
When ATH: N06BX
CCF: Preparation, improves blood circulation and metabolism of the brain
ICD-10 codes (testimony): F07, F07.2, F31, F32, F33, F41.2, F48.0, F79, G43, G93.4, H81, H81.0, H93.0, I61, I63, I67.2, I69, S06, T90
When CSF: 02.14.01
Manufacturer: Synthesis of (Russia)
Pharmaceutical form, composition and packaging
Capsules gelatin, size №0, white; contents of capsules – powder white or nearly white.
| 1 caps. | |
| piracetam | 400 mg |
| tsinnarizin | 25 mg |
Excipients: microcrystalline cellulose, lactose (milk sugar), magnesium stearate, talc.
Composition of gelatin capsules: Titanium dioxide, metilparagidroksiʙenzoat, propilparagidroksibenzoat, acetic acid, gelatin.
10 PC. – packings Valium planimetric (3) – packs cardboard.
10 PC. – packings Valium planimetric (6) – packs cardboard.
60 PC. – plastic jars (1) – packs cardboard.
Pharmacological action
Combined preparation, improves blood circulation and metabolism of the brain. Has a pronounced antihypoxic (mutually potencirovannym components), Neuroprotective and vasodilator effect. Contributes to a significant increase in blood flow in the brain.
Piracetam – Properties tool. Has a positive influence on the metabolism of the brain: increases in the concentration of ATP in brain tissue, increased synthesis of RNA and phospholipids, stimulates glikoliticaskie processes, increases glucose disposal.
Improves integrativuyu the brain, It contributes to memory consolidation, facilitates the learning process.
Modifies the speed of propagation of excitation in the brain, improves microcirculation, No sosudorasshiratego actions, suppress agregatia activated platelets.
Provides a protective effect of brain injuries, caused by hypoxia, poisoning, electroshock; enhances α- and β-activity, decreases δ-activity on EEG, decreases severity nystagmic vestibular.
Mezhnejronalnuju transfer and improves sinapticescuu conductivity in neokorticalnah structures, enhances mental performance, improves cerebral blood flow.
Effect develops gradually. Practically does not possess sedative and psihostimulirutm influence.
Therapeutic effect of piracetam is manifested through 1-6 no.
Tsinnarizin – selective blokator slow calcium channels, reduces the flow of calcium ions into cells and reduces its content in the depot plazmolemmy, lowers tone smooth muscles arteriol, reduces their response to biogenic vasoconstrictors (incl. epinephrine, norepinephrine, dofamin, Angiotensin, vasopressin, Serotonin).
Has a vasodilator effect (especially against cerebrovascular, reinforcing action pyracetam antihypoxia), without significant impact on HELL.
Shows moderate antigistaminnuu activity, reduces the excitability of the vestibular apparatus, reduces the tonus of the sympathetic nervous system.
In patients with impaired peripheral blood circulation improves blood flow to organs and tissues (incl. infarction), increases postishemicheskoe expansion vessels.
Increases elasticity of erythrocyte membranes, their ability to warp, reduces the viscosity of blood.
Toxicity of combination does not exceed the toxicity of individual components of the drug.
Pharmacokinetics
The drug is rapidly and completely absorbed from the digestive tract.
Piracetam
Absorption
Bioavailability of pyracetam – 95%. FROMmax pyracetam achieved through 2-6 no.
Distribution
Piracetam is not associated with blood plasma proteins. It penetrates through the BBB, placenta. Accumulate in brain tissue via 1-4 hours after ingestion. From cerebrospinal fluid appears much slower, than from other tissues.
Metabolism and excretion
Piracetam is almost not metabolized. T1/2 pyracetam from blood plasma is 4.5 no, T1/2 of the brain – average 7.7 no. Report mostly kidneys (more 95% the dose for 30 no).
Tsinnarizin
Absorption
FROMmax cinnarizina achieved through 1-4 no.
Distribution
Cmax cinnarizina through 1-4 h note not only in blood, as well as in the liver, kidney, heart, light, spleen and brain. The binding to plasma proteins – 91%.
Metabolism and excretion
Cinnarizine is completely metabolized in the liver (by dealkylation). T1/2 cinnarizina is 4 no. Appears in the form of metabolites (1/3 – Kidney with urine, 2/3 – through the intestine with feces).
Testimony
- Cerebrovascular accident (incl. when cerebrovascular, ischemic stroke, period of follow-up care after hemorrhagic stroke, After craniocerebral trauma);
- Encephalopathy different genesis;
-conditions after subkomatoznye and komatosnye intoxications and brain injury;
-central nervous system diseases, accompanied by a decrease in intellectual-mental functions;
— labirintopatii of different Genesis (accompanied by dizziness, tinnitus, nystagmus, nausea and vomiting), Meniere's syndrome;
- Depression;
— psihoorganiceski syndrome dominated signs of asthenia and adinamii;
-psychogenic asthenia;
-Prevention of migraine and kinetozov;
-impaired memory, cognitive function and concentration;
-backlog of intellectual development in children.
Dosage regimen
The drug is taken orally.
Adults by 1-2 caps. 3 times / day for 1-3 months depending on the severity of the disease.
Children under the age of 5 years by 1-2 caps. 1-2 times / day for 1-3 Months.
Courses of treatment spend 2-3 per year.
At chronic renal failure (CC<60 ml / min) It is necessary to reduce the dose or increase the interval between meals preparation.
Side effect
From the central and peripheral nervous system: irritability, sleep disturbance, headache, tremor of the extremities.
From the digestive system: dyspepsia, epigastric pain, dry mouth.
Allergic reactions: skin rash.
Contraindications
- Severe hepatic impairment;
- Severe renal insufficiency;
-Parkinson's disease;
- Pregnancy;
- Lactation;
- Children's age (to 5 years);
- Hypersensitivity.
FROM caution You should use the drug in Parkinson's disease, kidney and / or liver failure.
Pregnancy and lactation
Do not use this drug during pregnancy and breastfeeding.
Cautions
During treatment should monitor liver function.
At the beginning of treatment the patient should refrain from receiving alcohol.
In view of the content of cinnarizina drug may cause a positive reaction from the athletes when conducting doping test.
The drug should be wary when vnutriglaznom increased pressure.
Effects on ability to drive vehicles and management mechanisms
During treatment, it is necessary to be careful when driving and classroom activities, require high concentration and speed of psychomotor reactions.
Overdose
Data on overdose are not provided.
Drug Interactions
Kombitropil® do effects of medicines, CNS depressants, ethanol, as well as nootroponah and gipotenziveh funds.
Improves portability of antipsychotic drugs (neuroleptics) and tricyclic antidepressants.
Vazodilatirute medicines intensify the effect Kombitropila®.
Conditions of supply of pharmacies
The drug is released under the prescription.
Conditions and terms
List B. The drug should be stored out of reach of children, dry, dark place at a temperature no higher than 25 ° C. Shelf life – 2 year.
